Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA)…
RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma
Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to…
KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025
RIYADH, Saudi Arabia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist…
Adagenes ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
September 05, 2025 09:55 ET | Source: Adagene Inc. SAN DIEGO and…
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial…
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing…
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer…
Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001
CRANBERRY TOWNSHIP, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Jabez Biosciences, Inc.,…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are…
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in…
